Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights both positive and negative elements. Financial performance shows improved cost management and a solid cash position, but the increasing cash burn rate and high trial costs are concerning. Product development is promising with potential accelerated approval, but uncertainties in efficacy and patient recruitment pose risks. Market strategy is unclear with management avoiding direct responses. Shareholder returns are not mentioned. Overall, these mixed signals suggest a neutral stock price movement.
Key Financial Performance
Cash on Hand Approximately $13,000,000, which includes $9,000,000 raised in February 2025, providing a year-over-year increase due to successful capital raises.
Operating Expenses Reduced by about $3,000,000 in 2024 compared to 2023, indicating improved cost management.
Market Capitalization Current market cap is $16,200,000, up from year-end due to equity issuance in February 2025.
Shares Outstanding 14,000,000 shares outstanding, reflecting an increase due to recent equity issuance.
Cash Burn Rate $5,000,000 per quarter for the remainder of 2025, expected to increase to $7,000,000 or $8,000,000 per quarter in 2026 as CMC requirements for NDA are filled.
Trial Cost Estimate Estimated cost for the Phase III trial is upwards of $60,000,000 to $70,000,000.
Trading Volume Trailing one year trading volume is 1,400,000 shares per day, indicating active trading activity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MIRACLE Phase III Trial for Ranamycin: The trial is designed for approval of Ranamycin in combination with Cicerabine for relapsed and refractory AML patients, with 25 sites selected globally.
Anamycin Performance: Anamycin shows a 50% complete remission rate in second line therapy, significantly outperforming existing therapies.
Data Unblinding: Multiple unblinding of data will occur, with the first at 45 subjects expected by the end of this year.
Market Capitalization: Current market cap is $16.2 million, up from year-end due to equity issuance.
Cash Position: Combined cash balance of approximately $13 million, sufficient to fund operations into Q3 2025.
Operational Efficiency: Operating expenses reduced by $3 million in 2024 compared to 2023.
Site Selection and Approvals: Successfully contracted CROs and sites for the MIRACLE trial, with 25 sites selected and 45 more in process.
Focus on Anamycin Development: The company remains focused on Anamycin's development while relying on externally funded programs for WP1066 and WP1122.
Future Plans: Plans to expand Anamycin's use to first line therapy after demonstrating efficacy in second line therapy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Delays: The U.S. is expected to be one of the last countries to begin enrolling in the MIRACLE trial due to longer approval processes involving institutional review boards and hospital contract negotiations.
Clinical Trial Risks: The MIRACLE trial's success depends on achieving a statistically significant complete remission rate compared to historical data, which may be challenging given the competitive landscape.
Financial Risks: The overall cost of the Phase III trial is projected to be between $60 million to $70 million, with a cash burn of $5 million per quarter in 2025, increasing to $7-8 million in 2026.
Market Competition: There is a risk that competing therapies may emerge, which could impact the market potential for Anamycin, especially if they demonstrate superior efficacy or safety.
Data Reliability: The company relies on third-party sources for some data, which may not be independently verified, posing a risk to the credibility of the information presented.
Efficacy Uncertainty: The efficacy of Anamycin at the lower dosing regimen (190 mg/m²) compared to the higher dose (230 mg/m²) remains uncertain, which could affect trial outcomes and approval chances.
Patient Recruitment: The recruitment rate for the trial may be affected by the complexity of the study design and the need for specific patient populations, potentially delaying timelines.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
MIRACLE Phase III Trial Launch: The company is focused on launching the MIRACLE Phase III pivotal trial for Ranamycin, aimed at treating relapsed and refractory AML patients.
Patient Screening and Enrollment: Patient screening has begun, with expectations to treat the first patient in the current quarter.
Data Unblinding: The trial will have multiple unblinding of data, with the first expected after 45 subjects are treated.
Efficacy Expectations: The primary endpoint is complete remission after one cycle, with expectations of achieving significant results.
Market Positioning: Anamycin is positioned as a potential first non-cardiotoxic anthracycline, addressing a significant unmet need in AML.
Cash Position: The company has approximately $13 million in cash, expected to last into Q3 2025.
Operating Expenses: Operating expenses were reduced by about $3 million in 2024 compared to 2023.
Market Capitalization: Current market cap is $16.2 million with 14 million shares outstanding.
Future Milestones: Expect updates on trial site selection and approvals, data readouts, and unblinding of efficacy data by the end of 2025.
Cost of Phase III Trial: The overall cost of the Phase III trial is estimated to be between $60 million to $70 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Market Capitalization: $16,200,000 with 14,000,000 shares outstanding.
Cash Balance: Approximately $13,000,000 cash on hand at the end of the year, plus $9,000,000 raised in February 2025.
Operating Expenses: Reduced by about $3,000,000 in 2024 compared to 2023.
Cash Burn Rate: $5,000,000 per quarter for the rest of 2025, increasing to $7,000,000 or $8,000,000 per quarter in 2026.
Trial Cost Estimate: Overall cost of the Phase III trial estimated at $60,000,000 to $70,000,000.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What efficacy is required to pick one anamycin dose at forty five patients rather than waiting till ninety?
A:If we do as well in Part A, if Anamycin does as well as it did in the Phase two clinical trial and HYDAC simply performs as prior clinical trials have indicated, then we probably hit that number, that statistical significance that’s required to frankly shorten the trial and accelerate approval even faster.
Q:What was the thinking that went into cutting off about ten percent of patients from Part D?
A:That really came as a result of FDA when they review protocols will often comment and make suggestions. In this particular case, they specifically requested or suggested that we follow a slightly different biostatistical scheme than originally planned.
Q:What is the STS long net efficacy bogey you need to hit to proceed to even if it’s just an investigator sponsored pivotal trial?
A:We’ve frankly already hit that in really broad strokes. The STS patients we’ve treated turned out to be much more challenged than we originally expected.
Q:What are the overall costs of the trial?
A:If you go out to the full patient load, you’re talking upwards of $60,000,000 to $70 million. Our cash burn for the next rest of 2025 is $5,000,000 a quarter.
Q:What are your thoughts on moving to frontline once showing activity in the relapsed refractory setting?
A:Ultimately, it’s first line therapy, which is the biggest market because you don’t get the second or third line unless you were initially a first line therapy patient.
Q:What is the rationale for choosing the one hundred and ninety dose?
A:We chose two thirty for this study because two thirty got the great results we were seeing in our 106 study. For OPTIMUS, FDA wanted us to go to a lower dose.
Q:What dose do you anticipate using for the soft tissue sarcoma trial?
A:We’ve used a much higher dose. We’ve used just one each cycle is just one dose. We’re around three hundred milligrams per meter square.
Q:Do you have to be superior to the seventeen percent, eighteen percent that was observed to continue to perhaps apply for early?
A:If one dose is clearly superior to the other, let’s say two thirty has a much better complete response rate and similar safety, then the comparison would be the two thirty dose versus placebo.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specific efficacy required to pick one anamycin dose at forty five patients, stating it was a multi-variable equation and they would not speculate too much on the details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AML NDA
AML development
Anamycin Phase
Ashcroft Roth
Bernardino line
CMC requirement
Dr Weimach
FDA dose
HYDAC trial
MB
STS
Weimach Senior
anamycin
attention
choice
citerabine
course
cycle
efficacy safety
equation
line Chairman
line therapy
market line
percent
placebo
possibility
problem
profile
rationale
regimen
result dose
safety PK
significance
term
therapy patient
thinking
thought
trial Chairman
trial HYDAC
winner
MBRX Transcript
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates
Unknown5-14
The earnings call presents several risks and uncertainties: regulatory delays in the EU, a significant funding need of $15 million, and potential trial complications. Despite strong Annamycin performance and optimistic guidance, these risks overshadow positives. Additionally, the lack of new partnerships or shareholder return plans dampens sentiment. Given the small market cap, the stock may react strongly to these uncertainties, likely resulting in a negative movement of -2% to -8%.
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals. Positive factors include the EMA approval, new drug name recognition, and patent protection for Annamycin. However, the need for $15 million in funding and regulatory risks pose significant challenges. The Q&A section reveals uncertainties, particularly concerning EU approval timelines and R&D expenses. The small market cap suggests potential volatility, but the lack of clear positive catalysts and financial uncertainties balance the sentiment, leading to a neutral prediction.
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript
Unknown3-25
The earnings call summary highlights several risks, including regulatory delays, financial stability concerns, and competitive pressures. The Q&A section reveals management's vague responses and lack of clarity, further undermining confidence. Despite some positive aspects like reduced operating expenses and meeting certain efficacy requirements, the overall sentiment leans negative due to these uncertainties and risks.
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials
Unknown3-24
The earnings call highlights both positive and negative elements. Financial performance shows improved cost management and a solid cash position, but the increasing cash burn rate and high trial costs are concerning. Product development is promising with potential accelerated approval, but uncertainties in efficacy and patient recruitment pose risks. Market strategy is unclear with management avoiding direct responses. Shareholder returns are not mentioned. Overall, these mixed signals suggest a neutral stock price movement.
MBRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
